The COVID-19 pandemic highlights a need for the rapid development of detection strategies and assays for novel pathogens. The SARS-CoV-2 NGS Assay is a highly sensitive nucleic acid hybridization capture-based assay that detects the SARS-CoV-2 viral genome. This FDA-authorized-under-emergency-use assay combines virus-specific panels and comprehensive data analysis software and reporting capabilities to provide researchers with information on genetic variants, clade-associated variants, and phylogenetics. In this webinar brought to you by Twist Bioscience, Kristin Butcher and Mara Cuoto-Rodriguez will demonstrate the SARS-CoV-2 NGS assay technology and describe how researchers use it to detect and identify novel variants of the SARS-CoV-2 virus.
Topics to be covered
- The end-to-end SARS-CoV-2 NGS assay workflow
- The benefits of hybrid-capture technology and COVID-DX software
- How Biotia’s COVID-DX pipeline determines the presence or absence of SARS-CoV-2, identifies genetic variants, estimates viral clades, and generates phylogenetic trees
Meet the Speakers:
Director of Research and Development